---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-057035"
form_type: "8-K"
ticker: "FDMT"
cik: "0001650648"
company_name: "4D Molecular Therapeutics, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:10:51.600541+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# 4DMT Q1 2024 net loss $32.4M; advances 4D-150 toward Phase 3 for wet AMD

## Summary
- Net loss $32.4M in Q1 2024 vs $28.7M in Q1 2023.
- Cash $589M after $337M gross proceeds from upsized follow-on; runway into H1 2027.
- 4D-150 wet AMD: 89% injection burden reduction, 84% patients with 0-1 injections at 24 wks; Phase 3 start Q1 2025.
- Upcoming: 4D-150 broader wet AMD data at ASRS July 2024; 4D-710 CF interim data at ECFS June 2024.
- R&D expenses $27.9M, G&A $10.3M; both up YoY driven by clinical trial progression and headcount.

## SEC filing metadata
- accession: 0000950170-24-057035
- form_type: 8-K
- ticker: FDMT
- cik: 0001650648
- company_name: 4D Molecular Therapeutics, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650648/000095017024057035/0000950170-24-057035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650648/000095017024057035/fdmt-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-057035
- JSON: https://secwatch.observer/filing/0000950170-24-057035.json
- Plain text: https://secwatch.observer/filing/0000950170-24-057035.txt

## Key facts
- Earnings Releases
  4D Molecular Therapeutics, Inc. reported financial results for the three months ended March 31, 2024.
  - Period: the three months ended March 31, 2024
  - Result: reported results
  source text: 4D Molecular Therapeutics, Inc. (“4DMT”) announced its financial results for the three months ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1650648/000095017024057035/0000950170-24-057035-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.